Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry - PubMed (original) (raw)
Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry
L Ginaldi et al. Br J Haematol. 1996 Jun.
Abstract
Most T-cell antigens are expressed on normal and neoplastic T lymphocytes and for this reason it is not easy to distinguish between the immunophenotype of normal and malignant T cells. We have addressed this problem by comparing the levels of expression of CD3 and CD7 on T lymphocytes from 18 healthy donors with those of 61 cases of T-cell leukaemia using quantitative flow cytometry with a method that converts fluorescence intensity into number of antigen molecules per cell. Normal T lymphocytes expressed 124 +/- 25 CD3 and 20 +/- 3 x 10(3) CD7 molecules per cell. The mean CD3 values were significantly lower in all types of T-cell leukaemia than in normal T cells (P < 0.05), with the exception of Sezary syndrome. The lowest CD3 values were found in T-lymphoblastic leukaemia (T-ALL), 30 +/- 21 x 10(3), and adult T-cell leukaemia/lymphoma (ATLL), 38 +/- 31 x 10(3), followed by T-prolymphocytic leukaemia (T-PLL), 92 +/- 47 x 10(3), and granular lymphocyte leukaemia (GLL), 95 +/- 21 x 10(3). In contrast, the number of CD7 molecules was significantly higher in T-All, 35 +/- 7 x 10(3) (P < 0.01), and T-PLL, 29 +/- 12 x 10(3), than the normal controls (P < 0.01), whereas ATLL and GLL showed a low CD7 expression, 13 +/- 3 and 12 +/- 3 x 10(3), respectively. Our results show that the quantitative analysis of CD3 and CD7 and their combined evaluation may enable a distinction between normal and leukaemic T cells and could facilitate the monitoring of minimal residual disease. This study has also defined the T prolymphocyte as a cell of intermediate maturity between thymic derived and peripheral T lymphocytes.
Similar articles
- Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry.
Ginaldi L, Farahat N, Matutes E, De Martinis M, Morilla R, Catovsky D. Ginaldi L, et al. J Clin Pathol. 1996 Jul;49(7):539-44. doi: 10.1136/jcp.49.7.539. J Clin Pathol. 1996. PMID: 8813949 Free PMC article. - Base-edited CAR T cells for combinational therapy against T cell malignancies.
Georgiadis C, Rasaiyaah J, Gkazi SA, Preece R, Etuk A, Christi A, Qasim W. Georgiadis C, et al. Leukemia. 2021 Dec;35(12):3466-3481. doi: 10.1038/s41375-021-01282-6. Epub 2021 May 25. Leukemia. 2021. PMID: 34035409 Free PMC article. - The CD3 versus CD7 plot in multicolor flow cytometry reflects progression of disease stage in patients infected with HTLV-I.
Kobayashi S, Tian Y, Ohno N, Yuji K, Ishigaki T, Isobe M, Tsuda M, Oyaizu N, Watanabe E, Watanabe N, Tani K, Tojo A, Uchimaru K. Kobayashi S, et al. PLoS One. 2013;8(1):e53728. doi: 10.1371/journal.pone.0053728. Epub 2013 Jan 22. PLoS One. 2013. PMID: 23349737 Free PMC article. - [T-cell prolymphocytic leukemia: potential diagnostic pitfalls].
Dessart P, Lemaire P, Le Dû K, Sandrini J, Prophette B, Maillard H. Dessart P, et al. Ann Dermatol Venereol. 2014 Dec;141(12):777-81. doi: 10.1016/j.annder.2014.09.012. Epub 2014 Oct 23. Ann Dermatol Venereol. 2014. PMID: 25433931 Review. French. - T-cell associated antigen-positive B-cell lymphoma.
Inaba T, Shimazaki C, Sumikuma T, Nakagawa M. Inaba T, et al. Leuk Lymphoma. 2001 Nov-Dec;42(6):1161-71. doi: 10.3109/10428190109097741. Leuk Lymphoma. 2001. PMID: 11911397 Review.
Cited by
- Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
Hristov AC, Tejasvi T, A Wilcox R. Hristov AC, et al. Am J Hematol. 2021 Oct 1;96(10):1313-1328. doi: 10.1002/ajh.26299. Epub 2021 Aug 2. Am J Hematol. 2021. PMID: 34297414 Free PMC article. - Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Suurs FV, Lorenczewski G, Bailis JM, Stienen S, Friedrich M, Lee F, van der Vegt B, de Vries EGE, de Groot DA, Lub-de Hooge MN. Suurs FV, et al. J Nucl Med. 2021 Apr 30;62(12):1797-804. doi: 10.2967/jnumed.120.259036. Online ahead of print. J Nucl Med. 2021. PMID: 33931466 Free PMC article. - General quasi-equilibrium multivalent binding model to study diverse and complex drug-receptor interactions of biologics.
Ng CM, Bauer RJ. Ng CM, et al. J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):841-857. doi: 10.1007/s10928-024-09936-5. Epub 2024 Aug 17. J Pharmacokinet Pharmacodyn. 2024. PMID: 39153154 - Mycosis fungoides and Sézary syndrome.
Lee H. Lee H. Blood Res. 2023 Apr 30;58(S1):66-82. doi: 10.5045/br.2023.2023023. Blood Res. 2023. PMID: 37105561 Free PMC article. Review. - Pediatric T-cell prolymphocytic leukemia with an isolated 12(p13) deletion and aberrant CD117 expression.
Bellone M, Svensson AM, Zaslav AL, Spitzer S, Golightly M, Celiker M, Hu Y, Ma Y, Ahmed T. Bellone M, et al. Exp Hematol Oncol. 2012 Apr 18;1(1):7. doi: 10.1186/2162-3619-1-7. Exp Hematol Oncol. 2012. PMID: 23211022 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources